[
    [
        {
            "time": "",
            "original_text": "306家药企晒2020成绩单！超40家亏损，77家翻倍，云南白药、复星……狂赚超30亿亏损",
            "features": {
                "keywords": [
                    "药企",
                    "2020成绩单",
                    "亏损",
                    "翻倍",
                    "云南白药",
                    "复星"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "306家药企晒2020成绩单！超40家亏损，77家翻倍，云南白药、复星……狂赚超30亿亏损",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "西南证券：云南白药（000538.SZ）国企混改落地，维持“买入”评级",
            "features": {
                "keywords": [
                    "西南证券",
                    "云南白药",
                    "国企混改",
                    "买入评级"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券：云南白药（000538.SZ）国企混改落地，维持“买入”评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "西南证券--云南白药:国企混改落地，新白药快速启航【公司研究】",
            "features": {
                "keywords": [
                    "西南证券",
                    "云南白药",
                    "国企混改",
                    "新白药",
                    "启航"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券--云南白药:国企混改落地，新白药快速启航【公司研究】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]